|
Wingspan Stent’s Benefits Don’t Justify Risks, Panel Concludes
Stryker’s Wingspan stent could be yanked from the market if the FDA heeds March 23 recommendations of its Neurological Devices Panel.
This article is viewable by subscribers only. To view this article, please select an option below.
|
Subscribe
Archives